



CPBIO HOLDING COMPANY LIMITED

正大生物控股有限公司

Incorporated in Bermuda with members' limited liability • Stock Code : 3839

於百慕達註冊成立之成員有限責任公司 • 股份代號 : 3839

INTERIM REPORT 2026 中期報告

Contents

目錄

2	Management Discussion and Analysis 管理層討論及分析
6	Report on Review of Interim Financial Report 中期財務報告之審閱報告
8	Consolidated Statement of Comprehensive Income 綜合全面收益表
10	Consolidated Statement of Financial Position 綜合財務狀況表
12	Consolidated Statement of Changes in Equity 綜合權益變動表
14	Condensed Consolidated Statement of Cash Flows 簡明綜合現金流量表
15	Notes to Interim Financial Report 中期財務報告附註
31	Other Information 其他資料
35	Corporate Information 公司資料

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

GROUP RESULTS

The Group has two lines of business: biotech business and investment business. The biotech business focuses on animal health products and chlortetracycline (“CTC”), which accounts for all of the Group’s consolidated revenue and is carried on by Group subsidiaries. The investment business comprises the Group’s interests in its joint venture ECI Metro Investment Co., Ltd. (together with its subsidiaries, “ECI Metro”) and its associate Zhanjiang Deni Vehicle Parts Co., Ltd. (together with its subsidiaries, “Zhanjiang Deni”). The results of the Group’s investment business are incorporated in the consolidated statement of comprehensive income as share of profits and losses of joint venture and associate.

For the six months ended 30 June 2026 (“1H2026”), the Group’s revenue reduced by 34.6% to US\$211.4 million (for the six months ended 30 June 2025 (“1H2025”): US\$323.3 million). However, overall gross profit margin increased from 12.9% in 1H2025 to 16.4% in 1H2026. The decrease in revenue and the increase in overall gross profit margin came from our biotech business, which will be discussed below.

Profit attributable to shareholders of the Company dropped from US\$17.0 million in 1H2025 to US\$9.4 million in 1H2026.

Basic and diluted earnings per share were both 3.7 US cents (1H2025: 6.7 US cents). The Board of Directors of the Company resolved not to declare an interim dividend for the six months ended 30 June 2026 (1H2025: nil).

集團業績

本集團從事生物科技業務及投資業務。生物科技業務專注於動保化藥產品及金霉素，為本集團所有的綜合收入，並由本集團之附屬公司營運。投資業務包含本集團於ECI Metro Investment Co., Ltd. (及其附屬公司，統稱「ECI Metro」) 的合營企業權益及於湛江德利車輛部件有限公司 (及其附屬公司，統稱「湛江德利」) 的聯營公司權益。本集團投資業務的業績載列於綜合全面收益表內的應佔合營企業及聯營公司溢利及虧損。

截至二零二六年六月三十日止六個月 (「二零二六年上半年」)，本集團的收入下降34.6%至2億1,140萬美元 (截至二零二五年六月三十日止六個月 (「二零二五年上半年」)：3億2,330萬美元)。然而，整體毛利率從二零二五年上半年的12.9%上升至二零二六年上半年的16.4%。收入的減少及整體利潤率的增加來自生物科技業務，將在下文中討論。

本公司股東應佔溢利從二零二五年上半年1,700萬美元下降至二零二六年上半年940萬美元。

每股基本及攤薄溢利為3.7美仙 (二零二五年上半年：6.7美仙)。本公司董事會決議不派付截至二零二六年六月三十日止六個月的中期股息 (二零二五年上半年：無)。

BUSINESS REVIEW

Biotech business

We generate our revenue primarily from the manufacture and/or sale of animal health products and CTC products. Our animal health products are mainly preventive drugs for livestock diseases. CTC products, on the other hand, are antibiotics, used to prevent or cure animal diseases. In the past few years, we have been strategically broadening our product portfolio to cover related veterinary products. Of these new offerings, some we manufacture and sell, and some we source and trade. The Group's major customers include farms, feed mills, trading companies and pharmaceutical companies.

Due to a slowdown in the animal farming sector in China, demand for our animal health products also reduced since the third quarter of 2025. In 1H2026, the Group's revenue from the biotech business reduced by 34.6% to US\$211.4 million (1H2025: US\$323.3 million).

Our animal health products consist of a wide range of veterinary products. When compared to our CTC products, animal health products, on average, have lower profit margins. In 1H2026, revenue contribution from animal health products reduced due to a slowdown in the animal farming sector in China. As a result, overall gross profit margin increased from 12.9% in 1H2025 to 16.4% in 1H2026. Nevertheless, contribution from our biotech business declined in 1H2026.

Investment business

The Group's investment portfolio consists of ECI Metro and Zhanjiang Deni.

ECI Metro is principally engaged in the sale, leasing and servicing of Caterpillar machinery equipment in western China. Our revenue in 1H2026 from sales of excavators, power system and spare parts reduced by 15.2% as compared to that in 1H2025, mainly due to reduced demand for large-sized excavators and continuous challenges by domestic brands in China for small and medium-sized excavators. For the six months ended 30 June 2026, our share of loss of joint venture was US\$0.3 million (1H2025: profit of US\$1.4 million).

Zhanjiang Deni is principally engaged in the manufacture and sale of automotive parts, which are mainly sold to automobile and motorcycle manufacturers. In 1H2026, Zhanjiang Deni's sales of motorcycle parts and automotive parts both grew. For the six months ended 30 June 2026, our share of profit of associate increased from US\$0.8 million in 1H2025 to US\$1.2 million in 1H2026.

業務回顧

生物科技業務

我們的收入主要來自製造及／或銷售動保化藥產品和金霉素產品。我們的動保化藥產品主要是用作禽畜疾病的防治藥。而金霉素產品為用作預防或治療動物疾病的抗生素。近年，我們一直戰略性地擴大我們的產品系列，以涵蓋相關的獸藥產品。在這些新產品中，一部分我們製造及銷售，一部分我們採購和貿易。本集團的主要客戶包括養殖場、飼料加工廠、貿易公司及製藥公司。

由於中國養殖業放緩，對動保產品的需求也自二零二五年第三季隨之減弱。二零二六年上半年本集團生物科技業務的收入下降34.6%至2億1,140萬美元（二零二五年上半年：3億2,330萬美元）。

我們的動保化藥產品由廣大種類的獸藥產品組成。對比我們的金霉素產品，動保化藥產品的平均利潤率較低。二零二六年上半年，中國養殖業放緩致使我們的動保化藥產品收入佔比下降。因此，整體毛利率從二零二五年上半年的12.9%上升至二零二六年上半年的16.4%。儘管如此，我們的生物科技業務貢獻在二零二六年上半年有所下降。

投資業務

本集團的投資項目包含ECI Metro及湛江德利。

ECI Metro主要在中國西部從事卡特彼勒機械設備的銷售、租賃及維修服務。二零二六年上半年我們的挖掘機、發電機及零件銷售額比二零二五年上半年下降15.2%，主要由於大型挖掘機的需求減少，而中小型挖掘機持續受到國內品牌的挑戰。截至二零二六年六月三十日止六個月，應佔合營企業虧損為30萬美元（二零二五年上半年：溢利140萬美元）。

湛江德利主要從事製造及銷售汽車零件，主要出售予汽車及摩托車製造商。二零二六年上半年，湛江德利的摩托車零件銷售和汽車零件的銷售都有所增加。截至二零二六年六月三十日止六個月，應佔聯營公司溢利從二零二五年上半年的80萬美元上升至二零二六年上半年的120萬美元。

OUTLOOK

Looking forward, the slowdown in the animal farming sector in China and intensified competition are expected to bring uncertainties to our biotech business. Nevertheless, we will continue to implement our successful strategy to increase sales to key customers, broaden our product portfolio, and proactively expand into international markets to drive new business growth. Driven by steady growth in international sales over recent years, we see immense potential for further overseas expansion. By accelerating the growth of our global network, we expect international operations to become one of the major revenue and profit drivers of the Group.

Our June 2026 rebranding to “CPBIO Holding Company Limited” signals a strategic pivot, cementing our evolution into a fully integrated, biotechnology-driven enterprise. Going forward, the Group will anchor its growth on the core brand philosophy: “Comprehensive Solutions with Proven Results”. Taking a full value-chain approach, the Group has built end-to-end capabilities spanning research and development, manufacturing, technical services and global marketing. Anchored by a core portfolio of veterinary products, biological products and feed additives, and supported by biotechnology, precision nutrition and smart farming technologies, the Group delivers one-stop animal health solutions to commercial livestock producers globally. By addressing critical needs – from disease prevention and immune management to nutritional optimization, biosecurity, and antibiotic reduction – we directly drive operational efficiency, production resilience and food safety for our clients.

Overall, we remain cautiously optimistic about our performance in the second half of 2026.

LIQUIDITY AND FINANCIAL RESOURCES

As at 30 June 2026, the Group had total assets of US\$505.3 million, an increase of 9.5% as compared to US\$461.7 million as at 31 December 2025.

Net debt (30 June 2026: US\$38.0 million, 31 December 2025: US\$7.3 million) to equity ratio (defined as total bank borrowings minus cash and deposits divided by total equity) was 0.12 as compared to 0.02 as at 31 December 2025.

All the borrowings of the Group are denominated in Renminbi (“RMB”) as at 30 June 2026 and 31 December 2025.

As at 30 June 2026, the Group’s fixed interest rate bank borrowings amounted to US\$43.2 million (31 December 2025: US\$22.2 million).

展望

展望未來，中國養殖業放緩和競爭加劇預計會為我們的生物科技業務帶來不確定性。儘管如此，我們將繼續實施我們成功的開發大客戶銷售策略，擴大我們的產品系列，並積極拓展國際市場以打造新的業務增長點。近年來，本集團的海外銷售穩定增長，海外市場潛力巨大，本集團將加快完善全球業務網絡，海外業務有望成為本集團收入及盈利增長的重要驅動力。

本集團於今年六月正式更名為「正大生物控股有限公司」，標誌著本集團戰略定位的全面升級，體現本集團已全面轉型為以生物科技驅動增長的企業。未來，本集團將圍繞「全方位、實效」的品牌戰略核心，從全產業鏈思維出發，建立涵蓋產品研發、生產製造、技術服務及全球市場的完整能力體系。本集團以獸藥、生物製品及飼料添加劑為核心產品，以生物科技、精準營養及智能養殖為核心技術，為全球規模化養殖企業提供涵蓋疾病預防、免疫管理、營養提升、生物安全及抗生素替代的一站式動物健康解決方案，滿足關鍵需求，協助客戶提升養殖效率、生產韌性及食品安全水平。

我們對二零二六年餘下時間的表現保持謹慎樂觀態度。

資金流動性及財政資源

於二零二六年六月三十日，本集團之總資產為5億530萬美元，較二零二五年十二月三十一日之4億6,170萬美元，增加9.5%。

淨債務（二零二六年六月三十日：3,800萬美元，二零二五年十二月三十一日：730萬美元）對權益比率（定義為銀行借款減現金及存款後除以權益總額）為0.12，相對二零二五年十二月三十一日之0.02。

本集團於二零二六年六月三十日及二零二五年十二月三十一日的借款全部按人民幣作為單位。

於二零二六年六月三十日，本集團按固定利率計息之銀行借款為4,320萬美元（二零二五年十二月三十一日：2,220萬美元）。

All domestic sales in mainland China are transacted in RMB and export sales are transacted in foreign currencies. The Group monitors exchange rate movements and determines appropriate hedging activities when necessary.

CAPITAL STRUCTURE

The Group finances its working capital requirements through a combination of funds generated from operations and borrowings. The Group had cash and cash equivalents of US\$37.3 million as at 30 June 2026, decrease of US\$2.6 million compared to US\$39.8 million as at 31 December 2025.

CHARGES ON GROUP ASSETS

As at 30 June 2026, out of the total borrowings of US\$75.3 million (31 December 2025: US\$47.2 million) obtained by the Group, US\$11.3 million (31 December 2025: US\$6.0 million) was secured, which accounted for 15.1% (31 December 2025: 12.8%) of the total borrowings. Certain of the Group's property, plant and equipment and land lease prepayments with an aggregate net book value of US\$23.0 million (31 December 2025: US\$23.3 million) were pledged as security.

CONTINGENT LIABILITIES

As at 30 June 2026, the Group did not have any significant contingent liabilities.

SIGNIFICANT INVESTMENTS HELD, MATERIAL ACQUISITIONS AND DISPOSALS

Save for those disclosed in this interim report, there were no other significant investments held nor material acquisitions or disposals during the period.

EMPLOYEE AND REMUNERATION POLICIES

As at 30 June 2026, the Group employed around 1,000 employees in the Mainland China and Hong Kong. The Group remunerates its employees based on their performance, experience and prevailing market conditions while performance bonuses are granted on a discretionary basis. Other employee benefits include, for example, medical insurance and training.

於中國大陸所有國內銷售均以人民幣計算，而出口之銷售則以外幣計算。本集團監控外匯變動，必要時考慮適當的對沖活動。

資本結構

本集團透過營運資金及借款應付其流動資金需求。於二零二六年六月三十日，本集團持有現金及現金等價物3,730萬美元(二零二五年十二月三十一日：3,980萬美元)，減少260萬美元。

本集團資產抵押

於二零二六年六月三十日，本集團總借款為7,530萬美元(二零二五年十二月三十一日：4,720萬美元)，其中1,130萬美元(二零二五年十二月三十一日：600萬美元)借款需提供資產抵押，佔借款總額之15.1%(二零二五年十二月三十一日：12.8%)。本集團若干物業、廠房及設備及預付土地租賃費已用作抵押，賬面淨額合共2,300萬美元(二零二五年十二月三十一日：2,330萬美元)。

或有負債

本集團於二零二六年六月三十日並沒有任何重大或有負債。

持有的重大投資、重大收購及出售

除本中期報告所披露外，本集團在期內沒有持有任何其他重大投資，亦沒有進行任何重大收購或出售。

僱員及酬金政策

於二零二六年六月三十日，本集團於中國大陸及香港共聘用約1,000名僱員。本集團根據僱員的表現、經驗及現行的市場水平，釐訂其薪津，並酌情授予花紅。其他僱員福利包括例如：醫療保險及培訓。

**REPORT ON REVIEW OF INTERIM
FINANCIAL REPORT**

Review report to the board of directors of
CPBIO Holding Company Limited
(Incorporated in Bermuda with members' limited liability)

Introduction

We have reviewed the interim financial report set out on pages 8 to 30 which comprises the consolidated statement of financial position of CPBIO Holding Company Limited (the "Company") and its subsidiaries (together, the "Group") as of 30 June 2026 and the related consolidated statement of comprehensive income, consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six month period then ended and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of an interim financial report to be in compliance with the relevant provisions thereof and International Accounting Standard 34, *Interim Financial Reporting*, issued by the International Accounting Standards Board. The directors are responsible for the presentation of the interim financial report in accordance with International Accounting Standard 34.

Our responsibility is to form a conclusion, based on our review, on the interim financial report and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Scope of review

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*, issued by the Hong Kong Institute of Certified Public Accountants. A review of the interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

中期財務報告之審閱報告

致正大生物控股有限公司董事會之審閱報告
(於百慕達註冊成立之成員有限責任公司)

緒言

我們已審閱第8至30頁所載之中期財務報告，當中包括正大生物控股有限公司（「貴公司」）及其附屬公司（以下統稱「貴集團」）於二零二六年六月三十日的綜合財務狀況表與截至該日止六個月期間的相關綜合全面收益表、綜合權益變動表和簡明綜合現金流量表及附註解釋。香港聯合交易所有限公司證券上市規則規定，中期財務報告之編製必須符合當中有關條文，以及由國際會計準則委員會頒佈的國際會計準則第34號*中期財務報告*。董事須負責根據國際會計準則第34號編製及呈報中期財務報告。

我們的責任是根據我們的審閱對中期財務報告作出結論，並按照我們雙方所協定之委聘條款僅向全體董事會報告，且不可作其他用途。我們不會就本報告的內容，對任何其他人士負責或承擔任何責任。

審閱範圍

我們已根據香港會計師公會頒佈的香港審閱工作準則第2410號*獨立核數師對中期財務信息的審閱*進行審閱。審閱中期財務報告包括向主要負責財務和會計事務之人員作出查詢，並應用分析性和其他審閱程序。由於審閱範圍遠少於根據香港審核準則進行審核之範圍，故不能保證我們會知悉在審核中可能發現之所有重大事項。因此，我們不會發表審核意見。

**REPORT ON REVIEW OF INTERIM
FINANCIAL REPORT (CONTINUED)****中期財務報告之審閱報告(續)****Conclusion****結論**

Based on our review, nothing has come to our attention that causes us to believe that the interim financial report as at 30 June 2026 is not prepared, in all material respects, in accordance with International Accounting Standard 34, *Interim Financial Reporting*.

根據我們的審閱，我們並無發現任何事項令我們相信截至二零二六年六月三十日之中期財務報告在各重大方面未有根據國際會計準則第34號中期財務報告編製。

KPMG
Certified Public Accountants
8th Floor, Prince's Building
10 Chater Road
Central, Hong Kong

畢馬威會計師事務所
執業會計師
香港中環
遮打道10號
太子大廈8樓

11 August 2026

二零二六年八月十一日

CONSOLIDATED STATEMENT OF
COMPREHENSIVE INCOME

綜合全面收益表

			Six months ended 30 June 截至六月三十日止六個月	
			2026 二零二六年 US\$'000 美元千元 (Unaudited) (未經審核)	2025 二零二五年 US\$'000 美元千元 (Unaudited) (未經審核)
		Note 附註		
REVENUE	收入	5	211,389	323,328
Cost of sales	銷售成本		(176,661)	(281,545)
Gross profit	毛利		34,728	41,783
Other income, net	其他收入淨額	6	673	1,788
Selling and distribution costs	銷售及分銷成本		(9,100)	(7,539)
General and administrative expenses	行政及管理費用		(13,207)	(12,900)
Finance costs	財務成本	7	(589)	(1,059)
Share of profits and losses of:	應佔溢利及虧損：			
Joint venture	合營企業		(287)	1,350
Associate	聯營公司		1,237	783
PROFIT BEFORE TAX	除稅前溢利	8	13,455	24,206
Income tax	所得稅	9	(3,306)	(4,217)
PROFIT FOR THE PERIOD	期內溢利		10,149	19,989
Profit attributable to:	溢利歸屬予：			
Shareholders of the Company	本公司股東		9,423	17,046
Non-controlling interests	非控制性權益		726	2,943
			10,149	19,989
			US cents 美仙	US cents 美仙
EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY	本公司股東應佔之每股溢利			
Basic and diluted	基本及攤薄	11	3.70	6.70

CONSOLIDATED STATEMENT OF
COMPREHENSIVE INCOME (CONTINUED)

綜合全面收益表(續)

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年	2025 二零二五年
		US\$'000 美元千元	US\$'000 美元千元
		(Unaudited) (未經審核)	(Unaudited) (未經審核)
PROFIT FOR THE PERIOD	期內溢利	10,149	19,989
OTHER COMPREHENSIVE INCOME	其他全面收益		
Items that may be reclassified subsequently to profit or loss:	其後可能會重新分類至損益之項目：		
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之匯兌差額	4,025	1,988
Share of other comprehensive income of:	應佔其他全面收益：		
Joint venture	合營企業	3,380	2,001
Associate	聯營公司	755	415
Fair value change in financial asset at fair value through other comprehensive income ("FVOCI")	按公允價值計入其他全面收益之金融資產的公允價值變動	98	—
Income tax effect on fair value change in financial asset at FVOCI	按公允價值計入其他全面收益之金融資產的公允價值變動之所得稅影響	(15)	—
OTHER COMPREHENSIVE INCOME FOR THE PERIOD	期內其他全面收益	8,243	4,404
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內全面收益總額	18,392	24,393
Total comprehensive income attributable to:	全面收益總額歸屬予：		
Shareholders of the Company	本公司股東	16,630	20,879
Non-controlling interests	非控制性權益	1,762	3,514
		18,392	24,393

CONSOLIDATED STATEMENT OF
FINANCIAL POSITION

綜合財務狀況表

			30 June 2026 二零二六年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2025 二零二五年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
	Note 附註			
NON-CURRENT ASSETS		非流動資產		
Property, plant and equipment	12	物業、廠房及設備	106,019	101,483
Right-of-use asset		使用權資產	222	155
Land lease prepayments		預付土地租賃費	4,568	4,493
Investments in joint venture		於合營企業的投資	108,651	105,558
Investments in associate		於聯營公司的投資	26,051	24,059
Financial asset at FVOCI		按公允價值計入其他 全面收益之金融資產	1,261	1,163
Goodwill		商譽	341	341
Other non-current assets		其他非流動資產	516	62
Total non-current assets		總非流動資產	247,629	237,314
CURRENT ASSETS		流動資產		
Inventories		存貨	38,436	32,912
Trade and bills receivables	13	應收貿易賬款及票據	155,867	131,352
Prepayments, deposits and other receivables		預付賬款、按金及 其他應收賬款	26,159	20,255
Cash and cash equivalents		現金及現金等價物	37,253	39,831
Total current assets		總流動資產	257,715	224,350
CURRENT LIABILITIES		流動負債		
Trade payables	14	應付貿易賬款	81,021	80,863
Other payables and accruals		其他應付賬款及預提費用	14,518	15,655
Bank borrowings		銀行借款	65,071	38,266
Income tax payables		應付所得稅	393	2,658
Lease liabilities		租賃負債	50	96
Total current liabilities		總流動負債	161,053	137,538
NET CURRENT ASSETS		淨流動資產	96,662	86,812
TOTAL ASSETS LESS CURRENT LIABILITIES		總資產減流動負債	344,291	324,126

CONSOLIDATED STATEMENT OF
FINANCIAL POSITION (CONTINUED)

綜合財務狀況表(續)

			30 June 2026 二零二六年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2025 二零二五年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
	Note 附註			
NON-CURRENT LIABILITIES	非流動負債			
Bank borrowings	銀行借款		10,203	8,884
Other non-current liabilities	其他非流動負債		999	1,193
Deferred tax liabilities	遞延稅項負債		6,565	6,012
Lease liabilities	租賃負債		251	156
Total non-current liabilities	總非流動負債		18,018	16,245
NET ASSETS	資產淨值		326,273	307,881
EQUITY	權益			
Equity attributable to shareholders of the Company	本公司股東應佔權益			
Issued capital	已發行股本	15	25,333	25,333
Reserves	儲備		268,442	251,812
			293,775	277,145
Non-controlling interests	非控制性權益		32,498	30,736
TOTAL EQUITY	權益總額		326,273	307,881

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 綜合權益變動表

Six months ended 30 June 2026

截至二零二六年六月三十日止六個月

Attributable to shareholders of the Company
本公司股東應佔

		Issued capital 已發行股本 US\$'000 美元千元 (Unaudited) (未經審核)	Capital reserve 資本儲備 US\$'000 美元千元 (Unaudited) (未經審核)	PRC reserve funds 中國儲備基金 US\$'000 美元千元 (Unaudited) (未經審核)	Investment revaluation reserve 投資重估儲備 US\$'000 美元千元 (Unaudited) (未經審核)	Exchange fluctuation reserve 外匯波動儲備 US\$'000 美元千元 (Unaudited) (未經審核)	Retained profits 未分配利潤 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)	Non-controlling interests 非控制性權益 US\$'000 美元千元 (Unaudited) (未經審核)	Total equity 權益總額 US\$'000 美元千元 (Unaudited) (未經審核)
At 1 January 2026	於二零二六年一月一日	25,333	23,454	19,634	-	1,780	206,944	277,145	30,736	307,881
Profit for the period	期內溢利	-	-	-	-	-	9,423	9,423	726	10,149
Other comprehensive income for the period:	期內其他全面收益：									
Exchange differences related to translation of foreign operations	與外地業務於換算時相關之匯兌差額	-	-	-	-	3,022	-	3,022	1,003	4,025
Share of other comprehensive income of:	應佔其他全面收益：									
Joint venture	合營企業	-	-	-	-	3,380	-	3,380	-	3,380
Associate	聯營公司	-	-	-	-	755	-	755	-	755
Fair value change in financial asset at FVOCI	按公允價值計入其他全面收益之金融資產的公允價值變動	-	-	-	59	-	-	59	39	98
Income tax effect on fair value change in financial asset at FVOCI	按公允價值計入其他全面收益之金融資產的公允價值變動之所得稅影響	-	-	-	(9)	-	-	(9)	(6)	(15)
Total comprehensive income for the period	期內全面收益總額	-	-	-	50	7,157	9,423	16,630	1,762	18,392
At 30 June 2026	於二零二六年六月三十日	25,333	23,454	19,634	50	8,937	216,367	293,775	32,498	326,273

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (CONTINUED) 綜合權益變動表(續)

Six months ended 30 June 2025

截至二零二五年六月三十日止六個月

		Attributable to shareholders of the Company 本公司股東應佔							
		Issued capital 已發行 股本 US\$'000 美元千元 (Unaudited) (未經審核)	Capital reserve 資本 儲備 US\$'000 美元千元 (Unaudited) (未經審核)	PRC reserve funds 中國 儲備基金 US\$'000 美元千元 (Unaudited) (未經審核)	Exchange fluctuation reserve 外匯 波動儲備 US\$'000 美元千元 (Unaudited) (未經審核)	Retained profits 未分配 利潤 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)	Non- controlling interests 非控制性 權益 US\$'000 美元千元 (Unaudited) (未經審核)	Total equity 權益 總額 US\$'000 美元千元 (Unaudited) (未經審核)
At 1 January 2025	於二零二五年一月一日	25,333	17,106	19,517	(8,537)	181,354	234,773	25,739	260,512
Profit for the period	期內溢利	-	-	-	-	17,046	17,046	2,943	19,989
Other comprehensive income for the period:	期內其他全面收益：								
Exchange differences related to translation of foreign operations	與外地業務於換算時 相關之匯兌差額	-	-	-	1,417	-	1,417	571	1,988
Share of other comprehensive income of:	應佔其他全面收益：								
Joint venture	合營企業	-	-	-	2,001	-	2,001	-	2,001
Associate	聯營公司	-	-	-	415	-	415	-	415
Total comprehensive income for the period	期內全面收益總額	-	-	-	3,833	17,046	20,879	3,514	24,393
At 30 June 2025	於二零二五年六月三十日	25,333	17,106	19,517	(4,704)	198,400	255,652	29,253	284,905

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

簡明綜合現金流量表

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 US\$'000 美元千元 (Unaudited) (未經審核)	2025 二零二五年 US\$'000 美元千元 (Unaudited) (未經審核)
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動之現金流量		
Cash (used in)/generated from operations	經營(所用)/產生之現金	(17,903)	19,742
Interest paid	已付利息	(734)	(1,245)
Income tax paid	已付所得稅	(5,118)	(3,315)
Net cash flows (used in)/generated from operating activities	經營活動(所用)/所得現金流量淨額	(23,755)	15,182
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動之現金流量		
Payment for the purchase of property, plant and equipment	購買物業、廠房及設備所付款項	(5,816)	(1,150)
Other cash flows arising from investing activities	其他源自投資活動之現金流量	460	439
Net cash flows used in investing activities	投資活動所用之現金流量淨額	(5,356)	(711)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動之現金流量		
Proceeds from bank borrowings	銀行借款所得款項	43,482	24,092
Repayment of bank borrowings	償還銀行借款	(17,111)	(35,311)
Capital element of finance lease rental paid	已支付融資租賃租金中的本金部分	(57)	—
Interest element of finance lease rental paid	已支付融資租賃租金中的利息部分	(8)	—
Net cash flows generated from/(used in) financing activities	融資活動所得/(所用)之現金流量淨額	26,306	(11,219)
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物(減少)/增加淨額	(2,805)	3,252
Cash and cash equivalents at beginning of period	期初之現金及現金等價物	39,831	32,381
Effect of foreign exchange rate changes, net	外匯率變動之影響淨額	227	(143)
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末之現金及現金等價物	37,253	35,490

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

1. GENERAL INFORMATION

CPBIO Holding Company Limited (the “Company”) is a limited liability company incorporated in Bermuda. The Company and its subsidiaries hereinafter are collectively referred to as the “Group”. The Group is principally engaged in the manufacture and/or sale of animal health products and chlortetracycline (“CTC”). Additionally, the Group is also involved, through its joint venture and associated company, in the trading of machinery and the manufacture and sale of automotive parts.

At 30 June 2026, the directors consider the immediate holding company of the Company to be Charoen Pokphand Foods Public Company Limited (“CPF”), which is incorporated in the Kingdom of Thailand and shares of which are listed on the Stock Exchange of Thailand, and remains to be as such as at the date of approval of these financial statements. CPF is a significantly owned company of Charoen Pokphand Group Company Limited (“CPG”), which is incorporated in the Kingdom of Thailand.

2. BASIS OF PREPARATION

This interim financial report is unaudited and has been prepared in accordance with International Accounting Standard (“IAS”) 34 *Interim Financial Reporting* issued by the International Accounting Standards Board (the “IASB”) and the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The accounting policies and the basis of preparation adopted in the preparation of this interim financial report are consistent with those adopted in the annual financial statements for the year ended 31 December 2025, which were prepared in accordance with International Financial Reporting Standards (“IFRSs”) (which include all IFRSs, IASs and Interpretations) issued by the IASB, except for the accounting policy changes as set out in note 3 below. This interim financial report should be read in conjunction with the annual financial statements for the year ended 31 December 2025.

3. CHANGES IN ACCOUNTING POLICY AND DISCLOSURES

The Group has applied the amendments to IFRS 9, *Financial instruments* and IFRS 7, *Financial instruments: Disclosures – Amendments to the classification and measurement of financial instruments* issued by the IASB to this interim financial report for the current accounting period. The amendments do not have a material impact on this interim financial report.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

1. 一般資料

正大生物控股有限公司(「本公司」)為一家於百慕達註冊成立之有限公司。本公司及其附屬公司以下統稱為「本集團」。本集團主要從事製造及／或銷售動保化藥產品及金霉素。此外，本集團亦透過其合營企業及聯營公司從事機械設備貿易及產銷汽車零部件。

於二零二六年六月三十日，董事認為，本公司之直接控股公司為於泰國註冊成立的Charoen Pokphand Foods Public Company Limited(「CPF」)，其股份於泰國證券交易所上市，並於截至本財務報告獲批當日仍然為本公司的直接控股公司。CPF為一家於泰國註冊成立的Charoen Pokphand Group Company Limited(「CPG」)重大持有之公司。

2. 編製基準

此中期財務報告乃未經審核及按照國際會計準則委員會頒佈之國際會計準則(「國際會計準則」)第34號*中期財務報告*及香港聯合交易所有限公司證券上市規則(「上市規則」)適用之有關披露規定而編製。

除載列於以下附註3之會計政策更改外，此中期財務報告之會計政策及編製基準與截至二零二五年十二月三十一日止年度之年度財務報表所採用之會計政策及編製基準一致，乃按照國際會計準則委員會頒佈之國際財務報告準則(「國際財務報告準則」)(亦包括所有國際財務報告準則、國際會計準則及詮釋)而編製。此中期財務報告應與截至二零二五年十二月三十一日止年度之年度財務報表一併閱讀。

3. 會計政策及披露之更改

本集團已將國際會計準則委員會發布的《國際會計準則第9號—金融工具》及《國際會計準則第7號—金融工具：揭露—金融工具分類與計量的修訂》應用於本會計期間的中期財務報告。該修訂對本中期財務報告無重大影響。

本集團未採用任何尚未在本會計期間生效的新準則或詮釋。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has two reportable operating segments:

- the biotech business is principally engaged in the manufacture and/or sale of animal health products and chlortetracycline; and
- the investment business is principally engaged in the trading of machinery and the manufacture and sale of automotive parts, through the Group's joint venture and associate.

Management monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on reportable segment profit, which is a measure of adjusted profit before tax. The adjusted profit before tax is measured consistently with the Group's profit before tax except that bank interest income, finance costs and items not specifically attributed to individual segments, such as head office and corporate expenses are excluded from such measurements.

Segment assets exclude unallocated corporate assets. Unallocated corporate assets include cash and cash equivalents and other assets that are managed on a group basis.

Segment liabilities exclude unallocated corporate liabilities. Unallocated corporate liabilities include bank borrowings, income tax payables, deferred tax liabilities and other liabilities that are managed on a group basis.

All revenue from contracts with customers is recognised at the point in time when our customer obtains control of the promised goods, i.e. when products are delivered to the customers' premises for domestic sales or in accordance with the terms and conditions of sale for export sales. The major product line of the Group is the manufacture and/or sale of animal health products and chlortetracycline and in the biotech business as disclosed in note 4(a).

Disaggregation of revenue from contracts with customers by geographical location of customers is disclosed in note 4(b)(i).

4. 經營分類資料

按管理所需，本集團將業務按產品及服務分成兩個可呈報經營分類：

- 生物科技業務代表主要製造及／或銷售動保化藥產品及金霉素；及
- 投資業務代表主要機械設備貿易及產銷汽車零部件（透過本集團之合營企業及聯營公司）。

管理層會獨立監察本集團經營分類之業績而作出資源分配之決定及評定其表現。分類表現評估乃根據可呈報分類之溢利，即以經調整稅前溢利計算。經調整稅前溢利之計算與本集團稅前溢利之計算一致，除銀行利息收入、財務成本及不屬於個別分類之項目，如總部及企業開支不包括在其計算當中。

分類資產不包括未分配企業資產。未分配企業資產包括現金及現金等價物及其他在集團層面管理之資產。

分類負債不包括未分配企業負債。未分配企業負債包括銀行借款、應付所得稅、遞延稅項負債及其他在集團層面管理之負債。

所有源自與客戶的合約收入於客戶獲得承諾產品之控制權之時點確認，即於產品送達客戶場地時（國內銷售）或按照銷售條款和條件（出口銷售）。本集團主要的產品線為生化分類之製造及／或銷售動保化藥產品及金霉素，如附註4(a)披露。

源自與客戶的合約收入按客戶所在地分類，並於附註4(b)(i)披露。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments

The following tables present revenue, profit or loss and certain assets, liabilities and expenditure information for the Group's reportable operating segments during the period.

Six months ended 30 June 2026

(a) 可呈報經營分類

以下報表為本集團各可呈報經營分類於期內之收入、損益及若干資產、負債及開支資料。

截至二零二六年六月三十日止六個月

		Biotech business 生物科技業務 US\$'000 美元千元 (Unaudited) (未經審核)	Investment business 投資業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment revenue	分類收入			
Sales to external customers	銷售予外來客戶	211,389	–	211,389
Segment results	分類業績			
The Group	本集團	14,071	(23)	14,048
Share of profits and losses of:	應佔溢利及虧損：			
Joint venture	合營企業	–	(287)	(287)
Associate	聯營公司	–	1,237	1,237
		14,071	927	14,998
Reconciliation:	調節項目：			
Bank interest income	銀行利息收入			460
Finance cost	財務費用			(589)
Unallocated head office and corporate expenses	未分配總部及企業開支			(1,414)
Profit before tax	除稅前溢利			13,455
Other segment information	其他分類資料			
Depreciation and amortisation	折舊及攤銷	4,626	–	4,626
Capital expenditure	資本開支	5,816	–	5,816

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

At 30 June 2026

於二零二六年六月三十日

		Biotech business 生物科技業務 US\$'000 美元千元 (Unaudited) (未經審核)	Investment business 投資業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment assets	分類資產	333,331	134,737	468,068
Reconciliation: Unallocated corporate assets	調節項目： 未分配企業資產			37,276
Total assets	總資產			505,344
Segment liabilities	分類負債	95,377	–	95,377
Reconciliation: Unallocated corporate liabilities	調節項目： 未分配企業負債			83,694
Total liabilities	總負債			179,071
Other segment information	其他分類資料			
Investments in joint venture	於合營企業的投資	–	108,651	108,651
Investments in associate	於聯營公司的投資	–	26,051	26,051

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

Six months ended 30 June 2025

截至二零二五年六月三十日止六個月

		Biotech business 生物科技業務 US\$'000 美元千元 (Unaudited) (未經審核)	Investment business 投資業務 US\$'000 美元千元 (Unaudited) (未經審核)	Total 總額 US\$'000 美元千元 (Unaudited) (未經審核)
Segment revenue	分類收入			
Sales to external customers	銷售予外來客戶	323,328	—	323,328
Segment results	分類業績			
The Group	本集團	24,465	(424)	24,041
Share of profits and losses of:	應佔溢利及虧損：			
Joint venture	合營企業	—	1,350	1,350
Associate	聯營公司	—	783	783
		24,465	1,709	26,174
Reconciliation:	調節項目：			
Bank interest income	銀行利息收入			439
Finance cost	財務費用			(1,059)
Unallocated head office and corporate expenses	未分配總部及企業開支			(1,348)
Profit before tax	除稅前溢利			24,206
Other segment information	其他分類資料			
Depreciation and amortisation	折舊及攤銷	4,478	—	4,478
Capital expenditure	資本開支	1,150	—	1,150

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(a) Reportable operating segments (Continued)

(a) 可呈報經營分類(續)

At 31 December 2025

於二零二五年十二月三十一日

		Biotech business 生物科技業務 US\$'000 美元千元 (Audited) (經審核)	Investment business 投資業務 US\$'000 美元千元 (Audited) (經審核)	Total 總額 US\$'000 美元千元 (Audited) (經審核)
Segment assets	分類資產	292,147	129,648	421,795
Reconciliation: Unallocated corporate assets	調節項目： 未分配企業資產			39,869
Total assets	總資產			461,664
Segment liabilities	分類負債	96,556	—	96,556
Reconciliation: Unallocated corporate liabilities	調節項目： 未分配企業負債			57,227
Total liabilities	總負債			153,783
Other segment information	其他分類資料			
Investments in joint venture	於合營企業的投資	—	105,558	105,558
Investments in associate	於聯營公司的投資	—	24,059	24,059

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

4. OPERATING SEGMENT INFORMATION (CONTINUED)

4. 經營分類資料(續)

(b) Geographical information

(b) 地區資料

(i) Revenue from external customers

(i) 來自外來客戶之收入

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 US\$'000 美元千元 (Unaudited) (未經審核)	2025 二零二五年 US\$'000 美元千元 (Unaudited) (未經審核)
Mainland China	中國大陸	147,711	267,093
Asia Pacific (excluding mainland China)	亞太地區(不包括中國大陸)	30,323	21,382
Americas	美洲	23,218	20,977
Europe and elsewhere	歐洲及其他地方	10,137	13,876
		211,389	323,328

The revenue information shown above is based on the location of customers.

上列收入資料乃按客戶所在地分類。

(ii) Non-current assets

(ii) 非流動資產

At 30 June 2026, 99% (31 December 2025: 99%) of the Group's non-current assets are located in mainland China.

於二零二六年六月三十日，本集團99% (二零二五年十二月三十一日：99%) 之非流動資產均位於中國大陸。

5. REVENUE

5. 收入

Revenue represents the aggregate of the invoiced value of goods sold, net of value-added tax and government surcharges, and after allowances for goods returned and trade discounts recognised within the scope of IFRS 15. All of the Group's revenue is from the biotech business.

收入指除增值稅及政府附加費，及扣除退貨及貿易折扣後之累積銷售發票淨額並在國際財務報告準則第15號的範圍內確認。所有本集團之收入均來自生物科技業務。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

6. OTHER INCOME, NET

6. 其他收入淨額

An analysis of other income, net is as follows:

其他收入淨額分析如下：

		Six months ended 30 June 截至六月三十日止六個月	
		2026	2025
		二零二六年	二零二五年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Bank interest income	銀行利息收入	460	439
Government grants	政府補助	482	731
Loss on disposal of property, plant and equipment, net	出售物業、廠房及設備虧損淨額	–	(537)
Foreign exchange differences, net	外幣折算差異淨額	(680)	881
Others	其他	411	274
		673	1,788

7. FINANCE COSTS

7. 財務成本

		Six months ended 30 June 截至六月三十日止六個月	
		2026	2025
		二零二六年	二零二五年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Interest expense on bank borrowings	銀行借款之利息費用	734	1,245
Less: Interest expense capitalised*	減：利息費用資本化*	(153)	(186)
Interest expense on lease liabilities	租賃負債之利息費用	8	–
		589	1,059

* Interest expense was capitalised at interest rate based on the respective loan facilities of 2.2%-4.0% per annum (six months ended 30 June 2025: 2.6%-4.2% per annum).

* 利息費用資本化乃按各貸款協議之年利率2.2%至4.0%（二零二五年六月三十日止六個月：年利率2.6%至4.2%）計算。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

8. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging:

8. 除稅前溢利

本集團除稅前溢利經扣除下列各項：

		Six months ended 30 June 截至六月三十日止六個月	
		2026	2025
		二零二六年	二零二五年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Cost of inventories sold	已出售存貨成本	176,661	281,545
Depreciation of property, plant and equipment	物業、廠房及設備之折舊	4,563	4,419
Amortisation of land lease prepayments	預付土地租賃費之攤銷	63	59

9. INCOME TAX

No provision for Hong Kong profits tax has been made for the period as the Group did not generate any assessable profits in Hong Kong during the current period (six months ended 30 June 2025: nil).

Subsidiaries operating in the People's Republic of China ("PRC") are subject to income tax at the rate of 25% (six months ended 30 June 2025: 25%) on their taxable income according to the PRC corporate income tax laws. In accordance with the relevant tax rules and regulations in the PRC, certain subsidiaries of the Group in the PRC enjoy income tax exemptions or reductions.

9. 所得稅

本集團於本期內未有在香港賺取任何應課稅收入，所以未於期內作香港利得稅撥備（截至二零二五年六月三十日止六個月：無）。

根據中國企業所得稅稅例，於中華人民共和國（「中國」）經營之附屬公司需就其應課稅收入按稅率25%（截至二零二五年六月三十日止六個月：25%）繳交所得稅。根據中國之相關稅務守則及法例，本集團於中國之若干附屬公司享有豁免或減收所得稅之優惠。

		Six months ended 30 June 截至六月三十日止六個月	
		2026	2025
		二零二六年	二零二五年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Current – the PRC	本期－中國		
Charge for the period	期內支出	2,787	4,121
Under/(over)-provision in prior years	往年少／（多）計提	13	(896)
Deferred	遞延	506	992
Total tax expense for the period	期內稅項總支出	3,306	4,217

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

9. INCOME TAX (CONTINUED)

The Group is within the scope of the Pillar Two model rules published by the OECD. Under the rules, the Group is liable to pay a top-up tax for the difference between their Global Anti-Base Erosion (GloBE) effective tax rate per jurisdiction and the 15 per cent minimum rate. Of the various jurisdictions where the Group operates, Pillar Two legislation has not yet been substantially enacted in the Mainland China at 30 June 2026. However, Pillar Two legislation have been enacted in Hong Kong during the financial year 2025 with effective date set retrospectively from the financial year beginning on or after 1 January 2025. The top-up tax for the Group's Hong Kong companies was negligible in the current period as there was no taxable income to be incurred by these entities during the current period.

10. INTERIM DIVIDEND

The board has resolved not to declare an interim dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

11. EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY

The calculation of basic earnings per share is based on the profit for the period attributable to shareholders of the Company and the weighted average number of ordinary shares and convertible preference shares in issue during the period.

The calculation of basic earnings per share is based on the following data:

9. 所得稅(續)

本集團屬於經濟合作暨發展組織發布的支柱二示範規定的範圍。根據規定，本集團有責任根據每個司法管轄區的全球反侵蝕稅基有效稅率與15%的最低稅率之間的差額繳納補足稅。在本集團經營業務的多個司法管轄區中，截至二零二六年六月三十日，支柱二立法尚未在中國內地實質性頒布。然而，支柱二立法在香港已於二零二五年財政年度頒布，生效日期可追溯至二零二五年一月一日或之後開始的財政年度。於本期內，本集團之香港公司所產生的補足稅金額可忽略不計，原因是該等實體在本期內並未有產生任何應課稅收入。

10. 中期股息

董事會決議截至二零二六年六月三十日止六個月不派付中期股息(截至二零二五年六月三十日止六個月：無)。

11. 本公司股東應佔之每股溢利

每股基本溢利金額之計算乃根據本公司股東應佔期內溢利及期內已發行之普通股及可換股優先股加權平均數。

每股基本溢利乃根據以下數據計算：

	Six months ended 30 June	
	截至六月三十日止六個月	
	2026	2025
	二零二六年	二零二五年
	US\$'000	US\$'000
	美元千元	美元千元
	(Unaudited)	(Unaudited)
	(未經審核)	(未經審核)
Earnings		
Profit for the period attributable to shareholders of the Company, used in the basic earnings per share calculation		
溢利		
用於計算每股基本溢利之本公司股東本期應佔溢利		
	9,423	17,046

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

11. EARNINGS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY (CONTINUED)

11. 本公司股東應佔之每股溢利(續)

		Six months ended 30 June 截至六月三十日止六個月	
		2026 二零二六年 (Unaudited) (未經審核)	2025 二零二五年 (Unaudited) (未經審核)
Shares	股份		
Weighted average number of ordinary shares and convertible preference shares in issue during the period, used in the basic earnings per share calculation	用於計算每股基本溢利之 期內已發行之普通股及 可換股優先股加權平均數	253,329,087	253,329,087

As there were no potential dilutive ordinary shares during the six months ended 30 June 2026 and 2025, the amount of diluted earnings per share is equal to basic earnings per share.

於二零二六及二零二五年六月三十日止六個月期間並無潛在攤薄普通股，故每股攤薄溢利相等於每股基本溢利。

12. PROPERTY, PLANT AND EQUIPMENT

12. 物業、廠房及設備

		2026 二零二六年 US\$'000 美元千元 (Unaudited) (未經審核)	2025 二零二五年 US\$'000 美元千元 (Audited) (經審核)
At 1 January:	於一月一日：		
Cost	成本	181,394	171,489
Accumulated depreciation and impairment	累計折舊及減值	(79,911)	(71,850)
Net carrying amount	賬面淨值	101,483	99,639
Net carrying amount :	賬面淨值：		
At 1 January	於一月一日	101,483	99,639
Additions	添置	5,969	6,808
Acquisition of a subsidiary	收購附屬公司	-	1,036
Depreciation provided during the period	期內計提折舊	(4,563)	(9,316)
Disposals	出售	-	(971)
Exchange realignment	匯兌調整	3,130	4,287
At 30 June/31 December	於六月三十日／十二月三十一日	106,019	101,483
At 30 June/31 December:	於六月三十日／十二月三十一日：		
Cost	成本	187,363	181,394
Accumulated depreciation and impairment	累計折舊及減值	(81,344)	(79,911)
Net carrying amount	賬面淨值	106,019	101,483

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

13. TRADE AND BILLS RECEIVABLES

Depending on the requirements of the market and business, the Group may extend credit to its customers. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by management and interest may be charged by the Group for overdue trade receivable at rates determined by the Group with reference to market practice. In the opinion of the directors, there is no significant concentration of credit risk. An aging analysis of the Group's trade receivables (based on the date of delivery of goods) and bills receivables (based on issue date) are as follows:

		30 June 2026 二零二六年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2025 二零二五年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
Trade receivables:	應收貿易賬款：		
60 days or below	60日或以下	102,934	92,530
61 to 180 days	61至180日	45,418	33,372
Over 180 days	多於180日	6,549	4,437
		154,901	130,339
Bills receivables:	應收票據：		
60 days or below	60日或以下	547	547
61 to 180 days	61至180日	419	466
		966	1,013
		155,867	131,352

14. TRADE PAYABLES

An aging analysis of the Group's trade payables (based on the date of receipt of goods) as at the end of the reporting period are as follows:

14. 應付貿易賬款

本集團於報告期末應付貿易賬款(以收貨日期為基準)之賬齡分析如下：

		30 June 2026 二零二六年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2025 二零二五年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
Trade payables:	應付貿易賬款：		
60 days or below	60日或以下	63,275	62,953
61 to 180 days	61至180日	15,923	13,343
Over 180 days	多於180日	1,823	4,567
		81,021	80,863

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

15. SHARE CAPITAL

15. 股本

		30 June 2026 二零二六年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2025 二零二五年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
Authorised	法定		
<i>Ordinary shares:</i>	<i>普通股：</i>		
787,389,223 shares (31 December 2025: 787,389,223 shares) of US\$0.1 each	787,389,223股 (二零二五年十二月三十一日： 787,389,223股) 每股面值0.1美元	78,739	78,739
<i>Convertible preference shares:</i>	<i>可換股優先股：</i>		
12,610,777 shares (31 December 2025: 12,610,777 shares) of US\$0.1 each	12,610,777股 (二零二五年十二月三十一日： 12,610,777股) 每股面值0.1美元	1,261	1,261
		80,000	80,000
Issued and fully paid	已發行及繳足		
<i>Ordinary shares:</i>	<i>普通股：</i>		
240,718,310 shares (31 December 2025: 240,718,310 shares) of US\$0.1 each	240,718,310股 (二零二五年十二月三十一日： 240,718,310股) 每股面值0.1美元	24,072	24,072
<i>Convertible preference shares:</i>	<i>可換股優先股：</i>		
12,610,777 shares (31 December 2025: 12,610,777 shares) of US\$0.1 each	12,610,777股 (二零二五年十二月三十一日： 12,610,777股) 每股面值0.1美元	1,261	1,261
		25,333	25,333

There were no movements in the Company's issued ordinary shares and convertible preference shares during the six months ended 30 June 2026.

於截至二零二六年六月三十日止六個月內，本公司已發行普通股及可換股優先股概無變動。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

15. SHARE CAPITAL (CONTINUED)

Notes:

The convertible preference shares are convertible into ordinary shares of the Company and are entitled to the same dividends that are declared for the ordinary shares. Convertible preference shares do not carry the right to vote in shareholders' meeting. Upon winding up, the Company's residual assets and funds are distributed to the members of the Company in the following priority:

- (i) in paying to the holders of the convertible preference shares, pari passu as between themselves by reference to the aggregate nominal amounts of the convertible preference shares held by them respectively, an amount equal to the aggregate of the distribution value (as defined in the bye-laws of the Company) of all the convertible preference shares held by them respectively;
- (ii) the balance of such assets shall be distributed on a pari passu basis among the holders of any class of shares in the capital of the Company other than the convertible preference shares and other than any shares which are not entitled to participate in such assets, by reference to the aggregate nominal amounts paid up on the shares held by them respectively; and
- (iii) the remaining balance of such assets shall belong to and be distributed on a pari passu basis among the holders of any class of shares including the convertible preference shares, other than any shares not entitled to participate in such assets, by reference to the aggregate nominal amounts of shares held by them respectively.

The convertible preference shares shall be non-redeemable by the Company or the holders thereof.

16. CAPITAL COMMITMENTS

The Group had the following capital commitments as at the end of the reporting period:

Contracted, but not provided for:
Property, plant and machinery

已簽約，但尚未作出撥備：
物業、廠房及機器

15. 股本(續)

附註：

可換股優先股可轉換成本公司普通股及可收取與普通股持有人同等之股息。可換股優先股於股東會議不設投票權。於清盤時，本公司股東按以下次序分配本公司餘下資產及資金：

- (i) 向可換股優先股之持有人(彼等之間地位相等)參照彼等各自持有之可換股優先股面值總額支付相等於彼等各自持有之全部可換股優先股分派價值(於本公司細則中定義)總額之金額；
- (ii) 該等資產之結餘將按同等地位基準向本公司股本中任何類別股份(可換股優先股及無權參與分派該等資產之任何股份除外)之持有人(參照彼等各自持有之股份面值總額)予以分派；及
- (iii) 該等資產餘下之結餘將屬於並按同等地位基準向任何類別股份(包括可換股優先股但不包括無權參與分派該等資產之任何股份)之持有人(參照彼等各自持有之股份面值總額)予以分派。

本公司或持有人均不會對可換股優先股作出回購。

16. 資本承擔

本集團於報告期末之資本承擔如下：

	30 June 2026 二零二六年 六月三十日 US\$'000 美元千元 (Unaudited) (未經審核)	31 December 2025 二零二五年 十二月三十一日 US\$'000 美元千元 (Audited) (經審核)
Contracted, but not provided for: Property, plant and machinery	17,563	3,806

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

17. RELATED PARTY TRANSACTIONS

17. 關連交易

(a) Transactions with related parties

(a) 與關連人士的交易

The Group had the following transactions with related parties during the period:

本集團於期內與關連人士有以下的交易：

		Six months ended 30 June	
		截至六月三十日止六個月	
		2026	2025
		二零二六年	二零二五年
		US\$'000	US\$'000
		美元千元	美元千元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Sales of goods to:	銷售產品予：		
High Orient Enterprises Limited and its related entities*	High Orient Enterprises Limited及其關連企業*	103,510	217,129
Other related entities with same shareholders as CPG	與CPG有相同股東之其他關連企業	2,239	2,825
Purchase of goods from:	購買產品來自：		
ITOCHU Corporation and its subsidiaries*	伊藤忠商事株式會社及其附屬公司*	184	269

Note:

附註：

Prices of goods sold to related parties were determined with reference to the cost of raw materials, procurement costs, other value added, reasonable profit margins, market demand for goods and prices offered by independent third-party suppliers of similar products. The procedures to determine the prices of products sold to related parties are the same as those used to determine the prices of products supplied to independent third party customers. The selling prices to related parties shall be no more favourable than those made available to the Group's customers which are independent third parties.

向關連人士銷售的產品售價乃按原材料成本、採購成本、其他增值、合理的利潤率、市場對該產品之需求及由獨立第三方供應商提供類似產品的價格而釐定。釐定向關連人士銷售的產品售價的程序與釐定向獨立第三方客戶供應的產品售價所用者一致。向關連人士銷售的產品售價並不遜於本集團給予獨立第三方客戶之價格。

Prices and terms of goods purchased from related parties were on normal commercial terms and negotiated between the Group and related parties on an arm's length basis similar to those transactions which the Group conducts with independent third party suppliers and on terms which are no less favourable to the Group than those offered by independent third party suppliers.

向關連人士購買的產品售價和條款乃屬一般商業條款，經本集團與關連人士按公平原則磋商，類似本集團與獨立第三方供應商進行的交易及條款，及不遜於可由獨立第三方供應商提供予本集團之條款。

* These related party transactions also constituted continuing connected transactions as defined in Chapter 14A of the Listing Rules.

* 該等關連人士交易也構成上市規則第14A章內定義之持續關連交易。

NOTES TO INTERIM FINANCIAL REPORT

中期財務報告附註

17. RELATED PARTY TRANSACTIONS (CONTINUED)

17. 關連交易(續)

(b) Outstanding balances with related parties

(b) 與關連人士之間未清賬

- (i) Included in the Group's trade receivables as at 30 June 2026 were aggregate amounts of US\$110,367,000 (31 December 2025: US\$97,918,000) due from related companies, arising from transactions carried out in the ordinary course of business of the Group. The balances were unsecured, bore interest at rates determined by the Group after past due and were repayable within credit periods similar to those offered by the Group to its major independent third party customers.
- (ii) Included in the Group's prepayments, deposits and other receivables as at 30 June 2026 were aggregate amounts of US\$34,000 (31 December 2025: US\$33,000) and US\$2,867,000 (31 December 2025: US\$1,299,000) due from associate and related companies respectively. The balances were unsecured, interest-free and with no fixed terms of repayment.

- (i) 本集團於二零二六年六月三十日之應收貿易賬款包括本集團經營日常業務交易時所產生的應收關連公司之款項合計為1億1,036.7萬美元(二零二五年十二月三十一日: 9,791.8萬美元)。該等餘額乃無抵押、於過期後按本集團所定的利率計息及須於信貸期內償還(與本集團向主要獨立第三方客戶提供之利率及信貸期相若)。
- (ii) 本集團於二零二六年六月三十日之預付賬款、按金及其他應收賬款中, 包含合計3.4萬美元(二零二五年十二月三十一日: 3.3萬美元)及286.7萬美元(二零二五年十二月三十一日: 129.9萬美元)分別為應收聯營公司及關連公司之款項。該餘額均無抵押、免息及無固定還款期。

OTHER INFORMATION

其他資料

INTERIM DIVIDEND

The board of directors of the Company (the “Board”) has resolved not to declare an interim dividend for the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

DIRECTORS’ AND CHIEF EXECUTIVE’ INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at 30 June 2026, the interests and short positions of the directors and chief executive of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the “SFO”)) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) pursuant to Appendix C3 to the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”) – Model Code for Securities Transactions by Directors of Listed Issuers (the “Model Code”) are set out below:

Directors’ interests in shares of the Company (Long Positions)

Name of director	Capacity	Number of ordinary shares held	Approximate percentage of the issued ordinary share capital of the Company
董事名稱	身分	所持普通股股份數目	佔本公司已發行普通股股本概約百分比
Mr. Thirayut Phityaisarakul 李紹慶先生	Beneficial owner 實益擁有人	410,000	0.17%

Save as disclosed above, as at 30 June 2026, none of the directors or chief executive of the Company had any interests or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

中期股息

本公司董事會（「董事會」）決議截至二零二六年六月三十日止六個月不派付中期股息（截至二零二五年六月三十日止六個月：無）。

董事及行政總裁持有本公司及其相聯法團的股份、相關股份及債權證的權益及淡倉

於二零二六年六月三十日，根據證券及期貨條例第352條規定由本公司備存之登記冊的記錄，又或根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）附錄C3之上市發行人董事進行證券交易的標準守則（「標準守則」）向本公司及聯交所發出的通知，本公司董事及行政總裁持有本公司及其相聯法團（按證券及期貨條例第XV部所界定者）的股份、相關股份及債權證的權益及淡倉載列如下：

董事於本公司股份的權益（好倉）

除上述披露者外，於二零二六年六月三十日，根據證券及期貨條例第352條規定由本公司備存之登記冊的記錄，又或根據標準守則向本公司及聯交所發出的通知，概無任何本公司董事或行政總裁在本公司或其相聯法團（按證券及期貨條例第XV部所界定者）的股份、相關股份或債權證中擁有任何權益或淡倉。

SUBSTANTIAL SHAREHOLDERS AND PERSONS WHO HAVE INTERESTS OR SHORT POSITIONS WHICH ARE DISCLOSEABLE UNDER THE SECURITIES AND FUTURES ORDINANCE

主要股東及根據證券及期貨條例規定須予披露擁有權益或淡倉的人士

As at 30 June 2026, the following persons (not being a director or chief executive of the Company) had the following interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

於二零二六年六月三十日，根據證券及期貨條例第336條規定由本公司備存之登記冊的記錄，下列人士（非本公司的董事或行政總裁）於本公司的股份及相關股份擁有的權益及淡倉如下：

Name of shareholder	Notes	Capacity	Number of shares and underlying shares held	Approximate percentage of the issued ordinary share capital of the Company
股東名稱	附註	身分	持有股份及相關股份數目 (Note 1) (附註1)	已發行普通股股本概約百分比 (Note 1) (附註1)
Charoen Pokphand Group Company Limited	(2)	Interest of controlled corporation 受控制法團權益	127,748,147 (L)	53.07% (L)
Charoen Pokphand Foods Public Company Limited	(2)	Beneficial owner and interest of controlled corporation 實益擁有人及受控制法團權益	127,748,147 (L)	53.07% (L)
CPF Investment Limited	(2)	Beneficial owner 實益擁有人	115,137,370 (L)	47.83% (L)
ITOCHU Corporation 伊藤忠商事株式會社		Beneficial owner 實益擁有人	60,179,593 (L)	25.00% (L)
RAYS Capital Partners Limited		Investment manager 投資經理	12,051,500 (L)	5.00% (L)

Notes:

附註：

(1) The letter “L” denotes a long position.

(1) 「L」代表好倉。

(2) Charoen Pokphand Foods Public Company Limited (“CPF”) held 127,748,147 shares and underlying shares of the Company, which included (i) 115,137,370 ordinary shares beneficially owned by CPF’s wholly-owned subsidiary, CPF Investment Limited and (ii) 12,610,777 convertible preference shares beneficially owned by CPF. Charoen Pokphand Group Company Limited also declared interest in these shares by virtue of its shareholding interest in CPF.

(2) Charoen Pokphand Foods Public Company Limited (「CPF」) 持有127,748,147股本公司股份及相關股份，其中包括(i) CPF全資附屬公司CPF Investment Limited實益擁有的115,137,370股普通股及(ii) CPF實益擁有的12,610,777股可換股優先股。Charoen Pokphand Group Company Limited亦申報因擁有CPF的股權，故同樣擁有該等股份的權益。

Save as disclosed above, as at 30 June 2026, no persons (not being a director or chief executive of the Company) had any interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

除上述披露者外，於二零二六年六月三十日，根據證券及期貨條例第336條規定由本公司備存之登記冊的記錄，概無人士（非本公司董事或行政總裁）在本公司的股份或相關股份中擁有任何權益或淡倉。

SHARE OPTION SCHEME

The Company adopted a share option scheme (the “Share Option Scheme”) on 10 June 2025. During the six months ended 30 June 2026, no options were granted, exercised, cancelled, lapsed or outstanding under the Share Option Scheme. The number of options available for grant under the Share Option Scheme as at 1 January 2026 and 30 June 2026 was 24,071,831, being 10% of the total number of ordinary shares of the Company then in issue. As at the date of this interim report, the total number of ordinary shares which may be issued upon exercise of all options to be granted under the Share Option Scheme shall not in aggregate exceed 24,071,831 shares, being 10% of the total number of ordinary shares of the Company in issue on the date of approval of the shareholders meeting on 10 June 2025.

DISCLOSURE OF DIRECTORS’ INFORMATION PURSUANT TO RULE 13.51B(1) OF THE LISTING RULES

Directorships held in other public companies

Ms. Kobboon Srichai was appointed as a director of Charoen Pokphand Foods Public Company Limited (a company listed on the Stock Exchange of Thailand) with effect from 23 April 2026.

Other major appointments

Ms. Cheung Marn Kay was appointed as a Justice of the Peace by the Government of the Hong Kong Special Administrative Region with effect from 1 July 2026.

Directors’ Emolument

In April 2026, the Board approved to increase the monthly salary of Mr. Chawalit Na Muangtoun to RMB182,560, effective 1 March 2026, and to award him a discretionary bonus of RMB1,000,000.

In August 2026, the Board approved a monthly salary of HK\$280,200, effective 1 August 2026, to Mr. Soopakij Chearavanont in respect of his services.

購股權計劃

本公司於二零二五年六月十日採納購股權計劃（「購股權計劃」）。截至二零二六年六月三十日止六個月內，並無根據購股權計劃授出、行使、註銷、失效或尚未行使之購股權。於二零二六年一月一日至二零二六年六月三十日，根據購股權計劃可供售出的購股權數目為24,071,831，相當於本公司當時已發行普通股股份總數的10%。於本中期報告日期，根據購股權計劃將予授出的全部購股權獲行使時可予發行的普通股股份總數合共不得超過24,071,831股，相當於本公司於股東大會通過日期二零二五年六月十日已發行普通股股份總數的10%。

按上市規則第13.51B(1)條之董事資料披露

於其他上市公司擔任董事職務

Kobboon Srichai女士獲委任為Charoen Pokphand Foods Public Company Limited（一家於泰國證券交易所上市之公司）董事，自二零二六年四月二十三日生效。

其他主要的任命

章曼琪女士獲香港特別行政區政府委任為太平紳士，自二零二六年七月一日生效。

董事酬金

於二零二六年四月，董事會批准上調馬德壽先生之月薪至人民幣18.256萬元，自二零二六年三月一日生效，並向彼授予酌情花紅人民幣100萬元。

於二零二六年八月，董事會批准就謝吉人先生所提供之服務，授予其月薪28.02萬港元，自二零二六年八月一日生效。

CORPORATE GOVERNANCE CODE

The Company is committed to maintaining strict corporate governance standards. The principles of these standards are to uphold a high standard of ethics, transparency, accountability and integrity in all aspects of business and to ensure that affairs are conducted in accordance with applicable laws and regulations.

In the opinion of the Board, the Company has applied the principles and complied with all the code provisions prescribed in the Corporate Governance Code as set out in Appendix C1 to the Listing Rules throughout the six months ended 30 June 2026.

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the Code of Conduct for Securities Transactions, which is based on the required standard set out in the Model Code, as the code of conduct for dealings in the Company's securities by its directors. All Directors responded to a specific enquiry by the Company and confirmed that they complied with the required standard set out in the Code of Conduct for Securities Transactions during the six months ended 30 June 2026.

REVIEW OF INTERIM REPORT

The interim financial report for the six months ended 30 June 2026 is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants. KPMG's unmodified review report is set out on pages 6 to 7 of this interim report.

The audit committee of the Company has also reviewed the interim report for the six months ended 30 June 2026.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2026, neither the Company nor any of its subsidiaries have purchased, sold or redeemed any of the Company's listed securities.

By Order of the Board
Chawalit Na Muangtoun
Director

11 August 2026

企業管治守則

本公司致力保持嚴格的企業管治水平。其原則旨在維護公司在各業務方面均能貫徹高水平的道德、透明度、責任及誠信操守，並確保所有業務運作符合適用法律和法規。

董事會認為於二零二六年六月三十日止六個月內，本公司已應用載於上市規則附錄C1之企業管治守則的原則及遵守其所有守則條文。

董事的證券交易

本公司已採納證券交易行為守則，該守則乃根據標準守則所載的規定標準，作為其董事買賣本公司證券的行為守則。所有董事已回應本公司具體查詢並確認於截至二零二六年六月三十日止六個月內彼等遵守證券交易行為守則內所載的規定標準。

審閱中期報告

截至二零二六年六月三十日止六個月的中期財務報告為未經審核，但經畢馬威會計師事務所根據香港會計師公會頒佈的香港審閱工作準則第2410號獨立核數師對中期財務信息的審閱進行審閱。畢馬威會計師事務所的無修訂審閱報告已載於本中期報告的第6至7頁。

本公司審核委員會亦已審閱截至二零二六年六月三十日止六個月的中期報告。

購買、出售或贖回本公司的上市證券

截至二零二六年六月三十日止六個月內，本公司或其任何附屬公司概無購買、出售或贖回任何本公司的上市證券。

承董事會命
董事
馬德壽

二零二六年八月十一日

CORPORATE INFORMATION

公司資料

Chairman and Executive Director

Mr. Soopakij Chearavanont

董事長及執行董事

謝吉人先生

Executive Directors

Mr. Thirayut Phityaisarakul

Mr. Nopadol Chiaravanont

Mr. Chawalit Na Muangtoun (*Chief Executive Officer*)

執行董事

李紹慶先生

謝杰人先生

馬德壽先生 (*行政總裁*)

Non-executive Directors

Ms. Kobboon Srichai

Mr. Yoichi Ikezoe

非執行董事

Kobboon Srichai女士

池添洋一先生

Independent Non-executive Directors

Mr. Surasak Rounroengrom

Mr. Cheng Yuk Wo

Mr. Edward Ko Ming Tung

Ms. Cheung Marn Kay

獨立非執行董事

Surasak Rounroengrom先生

鄭毓和先生

高明東先生

章曼琪女士

Audit Committee

Mr. Cheng Yuk Wo (*Chairman*)

Mr. Surasak Rounroengrom

Mr. Edward Ko Ming Tung

審核委員會

鄭毓和先生 (*主席*)

Surasak Rounroengrom先生

高明東先生

Remuneration Committee

Mr. Cheng Yuk Wo (*Chairman*)

Ms. Cheung Marn Kay

Mr. Chawalit Na Muangtoun

薪酬委員會

鄭毓和先生 (*主席*)

章曼琪女士

馬德壽先生

Nomination Committee

Mr. Surasak Rounroengrom (*Chairman*)

Ms. Cheung Marn Kay

Mr. Thirayut Phityaisarakul

提名委員會

Surasak Rounroengrom先生 (*主席*)

章曼琪女士

李紹慶先生

Corporate Governance Committee

Mr. Edward Ko Ming Tung (*Chairman*)

Mr. Nopadol Chiaravanont

Mr. Chawalit Na Muangtoun

企業管治委員會

高明東先生 (*主席*)

謝杰人先生

馬德壽先生

Company Secretary

Mr. Lau Wing Yuen

公司秘書

劉永源先生

Registered Office

Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

註冊辦事處

Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

Principal Place of Business in Hong Kong

21st Floor, Far East Finance Centre
16 Harcourt Road, Hong Kong

香港主要營業地點

香港夏慤道16號
遠東金融中心21樓

Auditor

KPMG
Certified Public Accountants
Public Interest Entity Auditor
registered in accordance with
the Accounting and Financial Reporting Council Ordinance

核數師

畢馬威會計師事務所
執業會計師
於《會計及財務匯報局條例》下
的註冊公眾利益實體核數師

Principal Bankers

Bank of China
Bank of Communications
China Construction Bank

主要往來銀行

中國銀行
交通銀行
中國建設銀行

Share Registrars

Bermuda Principal Share Registrar
Ocorian Management (Bermuda) Limited
Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

股份過戶登記處

百慕達主要股份過戶登記處
Ocorian Management (Bermuda) Limited
Victoria Place, 5th Floor
31 Victoria Street
Hamilton HM 10
Bermuda

Hong Kong Branch Share Registrar
Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor, Hopewell Centre
183 Queen's Road East, Wanchai, Hong Kong

香港股份過戶登記分處
香港中央證券登記有限公司
香港灣仔皇后大道東183號
合和中心17樓1712-1716號舖

Shares Listing

The Stock Exchange of Hong Kong Limited
Stock Code: 3839

股份上市地點

香港聯合交易所有限公司
股份代號：3839

Website

www.cp-bio.com

網站

www.cp-bio.com



CPBIO HOLDING COMPANY LIMITED
正大生物控股有限公司

Incorporated in Bermuda with members' limited liability • Stock Code : 3839
於百慕達註冊成立之成員有限責任公司 • 股份代號 : 3839